A new proteomic scoring tool outperforms existing clinical methods at predicting kidney failure in people carrying high-risk APOL1 gene variants, pointing to a more targeted path for early intervention.
The genetic risk that slips through the cracks
Roughly 13% of Black Americans carry two copies of high-risk APOL1 gene variants, a genetic profile that dramatically raises the odds of developing serious kidney disease. The connection was first established in a landmark 2010 study, which identified these variants in people of African ancestry and linked them to elevated kidney disease rates. A 2013 follow-up confirmed the association with progression to end-stage kidney disease.
But carrying those variants does not guarantee a diagnosis. Most people with this genetic profile never develop significant kidney problems, while others deteriorate rapidly. That inconsistency has made it difficult for doctors to know who actually needs aggressive monitoring or early treatment.
Standard tools like the Kidney Failure Risk Equation, validated across multinational populations in 2016, rely primarily on estimated glomerular filtration rate, or eGFR, a measure of how well the kidneys filter waste from the blood. The problem is that by the time eGFR starts to fall, meaningful kidney damage may already have occurred.
What nine proteins can do that eGFR cannot
Researchers studying APOL1 high-risk carriers with preserved eGFR, meaning their kidney function still appears normal by conventional measures, have now identified a nine-protein plasma signature that predicts both kidney events and mortality with greater accuracy than existing tools.
The proteomic risk score outperformed both the Kidney Failure Risk Equation and APOL1 genotype-based stratification alone, which is notable because genotype on its own has had limited power in predicting which carriers will actually progress. The proteins in the signature are also biologically plausible, meaning they map onto known pathways involved in kidney stress and vascular injury rather than appearing as statistical noise.
That biological coherence matters. A 2026 mouse study found that inducible expression of APOL1 risk variants triggered vascular dysfunction and cellular stress, producing both hypertension and direct kidney damage. The proteins identified in the new scoring tool appear to reflect these same upstream processes, which strengthens the case that they are tracking real disease biology, not just correlating with it incidentally.
A tool built for the moment before intervention becomes harder
The clinical value of catching risk early in people with preserved kidney function is hard to overstate. Once eGFR begins declining, the treatment window narrows considerably. A risk score that flags danger before that decline offers two things: the chance to intervene earlier in individual patients, and a way to enrich clinical trials with the people most likely to benefit.
That second point has direct implications for drug development. In 2023, a clinical trial of inaxaplin, a drug that targets APOL1 pathways directly, showed measurable benefit in people with two APOL1 variants and proteinuria. But recruiting the right participants for such trials has historically been difficult, in part because APOL1 carriers at genuine short-term risk are hard to distinguish from those who may never progress.
A validated proteomic score could help solve that problem. By identifying who is on the steeper trajectory, researchers could enroll patients more precisely and design trials with greater statistical power using smaller populations.
What comes next for APOL1 screening
This research does not yet translate into a clinical test that patients can request at their next checkup. Proteomic profiling at scale remains expensive and logistically complex, and the score will need validation across additional populations before it could be incorporated into standard care pathways.
Still, the implications are significant for a population that has historically carried a disproportionate kidney disease burden with limited tools tailored specifically to their biological risk. For APOL1 carriers, a nine-protein blood signature may eventually offer what current medicine cannot: a reliable early warning.
